ATE286715T1 - Gastrointestinale an der mucosa haftende pharmazeutische zusammensetzung - Google Patents

Gastrointestinale an der mucosa haftende pharmazeutische zusammensetzung

Info

Publication number
ATE286715T1
ATE286715T1 AT98909852T AT98909852T ATE286715T1 AT E286715 T1 ATE286715 T1 AT E286715T1 AT 98909852 T AT98909852 T AT 98909852T AT 98909852 T AT98909852 T AT 98909852T AT E286715 T1 ATE286715 T1 AT E286715T1
Authority
AT
Austria
Prior art keywords
mucosa
pharmaceutical composition
composition adhesive
gastrointestinal
gastrointestinal pharmaceutical
Prior art date
Application number
AT98909852T
Other languages
English (en)
Inventor
Yohko Akiyama
Naoki Nagahara
Megumi Kitano
Masafumi Nakao
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of ATE286715T1 publication Critical patent/ATE286715T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT98909852T 1997-03-25 1998-03-24 Gastrointestinale an der mucosa haftende pharmazeutische zusammensetzung ATE286715T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP7140897 1997-03-25
PCT/JP1998/001284 WO1998042311A1 (en) 1997-03-25 1998-03-24 Gastrointestinal mucosa-adherent pharmaceutical composition

Publications (1)

Publication Number Publication Date
ATE286715T1 true ATE286715T1 (de) 2005-01-15

Family

ID=13459669

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98909852T ATE286715T1 (de) 1997-03-25 1998-03-24 Gastrointestinale an der mucosa haftende pharmazeutische zusammensetzung

Country Status (10)

Country Link
US (1) US6428813B1 (de)
EP (1) EP0973498B1 (de)
KR (1) KR20000076329A (de)
CN (1) CN1251035A (de)
AT (1) ATE286715T1 (de)
AU (1) AU740841B2 (de)
CA (1) CA2282531A1 (de)
DE (1) DE69828595T2 (de)
ID (1) ID22340A (de)
WO (1) WO1998042311A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ318282A (en) 1995-09-07 2000-01-28 Smithkline Beecham Corp Pharmaceutical formulation containing amoxycillin and clavulanate in a weight ratio of 12:1 and 20:1
NZ506280A (en) 1998-03-20 2001-08-31 Kowa Co Medicinal compositions adhering to stomach/duodenum
AU1890900A (en) * 1999-01-07 2000-07-24 Takeda Chemical Industries Ltd. Polyol compounds, their production and use
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US7250176B1 (en) * 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
PT102450B (pt) * 1999-04-13 2003-09-30 Beecham Pharm Pte Ltd Formulacao farmaceutica de libertacao modificada compreendendo amoxicilina e clavulanato de potassio e utilizacao destes compostos no fabrico de um medicamento para o tratamento de infeccoes bacterianas
WO2001015735A1 (fr) 1999-08-26 2001-03-08 Takeda Chemical Industries, Ltd. Matrice adherant a la muqueuse nasale
EP1330236A2 (de) 2000-10-12 2003-07-30 Beecham Pharmaceuticals (Pte) Limited Amoxicillinhaltige arzneizusammensetzungen
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
EP1245227A1 (de) 2001-03-31 2002-10-02 Jagotec Ag Pharmazeutische, im Magen aufschwimmende Tablette für die programmierte Freisetzung des Wirkstoffes und Verfahren zur Herstellung des in der Tablette enthaltenen schwimmfähigen Materials
FR2827771B1 (fr) * 2001-07-25 2003-10-24 Apis Spheromont Formulation et procede de preparation de spheroides pouvant etre fortement titres et a dispersion rapide
US20070059358A1 (en) * 2003-07-02 2007-03-15 Tianjin Tasly Pharmaceutical Co., Ltd., China Matrix adjuvants and the drop pills prepared with them
GB0321996D0 (en) 2003-09-19 2003-10-22 Novartis Nutrition Ag Organic compounds
CA2563533C (en) 2004-04-15 2013-10-01 Shmuel A. Ben-Sasson Compositions capable of facilitating penetration across a biological barrier
US20070048364A1 (en) * 2005-08-04 2007-03-01 Yingxu Peng Free flowing granules containing carbomer
US20080279921A1 (en) * 2007-05-07 2008-11-13 Ceramoptec Industries, Inc. Gel-formulations of hydrophobic photosensitizers for mucosal applications
ES2350029T3 (es) 2007-03-02 2011-01-17 Farnam Companies, Inc. Pellets de liberación sostenida que comprenden un material tipo cera.
US20090105561A1 (en) * 2007-10-17 2009-04-23 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Medical or veterinary digestive tract utilization systems and methods
US8303573B2 (en) 2007-10-17 2012-11-06 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8789536B2 (en) 2007-10-17 2014-07-29 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8707964B2 (en) * 2007-10-31 2014-04-29 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8808276B2 (en) * 2007-10-23 2014-08-19 The Invention Science Fund I, Llc Adaptive dispensation in a digestive tract
US8333754B2 (en) * 2007-10-31 2012-12-18 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8808271B2 (en) * 2007-10-31 2014-08-19 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8109920B2 (en) * 2007-10-31 2012-02-07 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US20090163894A1 (en) * 2007-10-31 2009-06-25 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Medical or veterinary digestive tract utilization systems and methods
US20090137866A1 (en) * 2007-11-28 2009-05-28 Searete Llc, A Limited Liability Corporation Of The State Delaware Medical or veterinary digestive tract utilization systems and methods
MX2011002836A (es) 2008-09-17 2011-04-28 Chiasma Inc Composiciones farmaceúticas y métodos de administración relacionados.
US11311570B2 (en) 2014-08-11 2022-04-26 Perora Gmbh Method of inducing satiety
WO2016023923A1 (en) * 2014-08-11 2016-02-18 Perora Gmbh Formulation comprising particles
MA41462A (fr) 2015-02-03 2021-05-12 Chiasma Inc Méthode de traitement de maladies
US11234935B2 (en) 2015-07-07 2022-02-01 Perora Gmbh Method of inducing satiety
KR101882820B1 (ko) * 2015-12-30 2018-07-30 주식회사 삼양바이오팜 점막부착성 약학 조성물 및 그의 제조방법
AU2017220691A1 (en) * 2016-02-18 2018-08-09 Perora Gmbh Kits comprising satiety-inducing formulations
CN112494443A (zh) * 2020-12-12 2021-03-16 海南海神同洲制药有限公司 精准缓释片及其制备方法
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3769707D1 (de) * 1986-06-17 1991-06-06 Recordati Chem Pharm Therapeutisches system mit geregelter wirkstoffabgabe.
US5654009A (en) * 1991-03-25 1997-08-05 Fujisawa Pharmaceutical Co., Ltd. Delayed action preparation
TW209174B (de) 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
US5409903A (en) * 1992-02-18 1995-04-25 Urecap Corporation Method and compositions for the treatment of H. pylori and dermatitis
SE9201930D0 (sv) 1992-06-24 1992-06-24 Astra Ab Gastric antibacterial treatment
ATE192932T1 (de) 1993-09-09 2000-06-15 Takeda Chemical Industries Ltd Formulierung enthaltend einen antibakteriellen und einen antiulcus wirkstoff
WO1997011705A1 (en) 1995-09-26 1997-04-03 Takeda Chemical Industries, Ltd. Phosphorylamides, their preparation and use
US6245351B1 (en) * 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
JP3947244B2 (ja) * 1996-04-04 2007-07-18 日清ファルマ株式会社 消化性潰瘍治療用製剤
GB9619072D0 (en) * 1996-09-12 1996-10-23 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
ID22340A (id) 1999-09-30
EP0973498A1 (de) 2000-01-26
WO1998042311A1 (en) 1998-10-01
DE69828595D1 (de) 2005-02-17
AU6422898A (en) 1998-10-20
EP0973498B1 (de) 2005-01-12
KR20000076329A (ko) 2000-12-26
CA2282531A1 (en) 1998-10-01
AU740841B2 (en) 2001-11-15
US6428813B1 (en) 2002-08-06
CN1251035A (zh) 2000-04-19
DE69828595T2 (de) 2006-01-05

Similar Documents

Publication Publication Date Title
ATE286715T1 (de) Gastrointestinale an der mucosa haftende pharmazeutische zusammensetzung
EE04002B1 (et) Peroraalne farmatseutiline annusvorm, mis sisaldab prootonpumba inhibiitorit ja antatsiidainet või alginaati
DE69910186D1 (de) Pharmazeutische zusammensetzung von topiramate
DK1028707T3 (da) Oftalmiske præparater med forlænget frigivelse og indeholdende vandopløselige medikamenter
ATE312602T1 (de) Orale pharmazeutische dosierungsform mit verlängerter wirkstofffreisetzung
FI980822A (fi) Farmaseuttinen koostumus vaikuttavan aineen iho- tai limakalvopintaan tai iho- tai limakalvopinnan läpi
ATE234078T1 (de) Pharmazeutische omeprazol-formulierung
EE200000232A (et) Farmatseutiline kompositsioon ja selle kasutamine
DE69622735D1 (de) Lyophilisierte stabile pharmazeutische formulierung
DE69525148D1 (de) Pharmazeutische formulierung
FI972292A0 (fi) Administrering av diabetes
ID18383A (id) Dosis farmasi oral yang mengandung penghambat pompa proton dan zat prokinetik
ID23673A (id) Formulasi farmasi yang terdiri dari amoksicilin dan klavulanat
ID22565A (id) Penggunaan nanodispersi dalam formulasi akhir obat
BR9607851B1 (pt) combinaÇço e formulaÇço farmacÊutica.
MX9202804A (es) Composicion farmaceutica y terapeutica que comprende una nueva molecula de adhesion intracelular.
PT864559E (pt) Compostos amino substituidos e sua utilizacao como substancias activas analgesicas
BR9602915A (pt) Medicamentos uso e formulação farmacêutica
DE69813602D1 (de) Venlafaxinhaltiges arzneimittel mit verlängerter wirkstoffabgabe
DE60037816D1 (de) Pharmazeutische formulierung enthaltend megalatran und dessen pro-pharmaka
NO20011217D0 (no) Doseringsform omfattende væskeformulering
DE59804823D1 (de) Arzneimittelformulierung mit kontrollierter wirkstofffreisetzung
ATE273697T1 (de) Pharmazeutische levothyroxinzubereitung
ATE225651T1 (de) Levothyroxin natrium enthaltende pharmazeutische zubereitung
IT1319210B1 (it) Pellicola per la somministrazione dermica e transdermica di principiattivi.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties